Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AR 101

Drug Profile

AR 101

Alternative Names: AR-101-Aimmune-Therapeutics; Characterised-peanut-allergen-oral-immunotherapy-ARC; CPNA-Aimmune-Therapeutics; PALFORZIA; Peanut allergy immunotherapy - Aimmune Therapeutics; Peanut allergy OIT - Aimmune Therapeutics

Latest Information Update: 19 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergen Research Corporation
  • Developer Aimmune Therapeutics; Regeneron Pharmaceuticals; Sanofi
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Peanut hypersensitivity

Most Recent Events

  • 06 Nov 2019 Aimmune therapeutics anticipates BLA approval in Peanut hypersensitivity (In children, In adolescents) by January 2020
  • 06 Nov 2019 Aimmune therapeutics expects EMA action date for MAA for Peanut hypersensitivity (In adolescents, In adults, In children) in H2 2020
  • 20 Sep 2019 Aimmune Therapeutics completes the phase III RAMSES OLE trial for Peanut hypersensitivity (In children, In adolescents) in USA and Canada (PO, Capsule) (NCT03337542)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top